Preliminary Q2 2022 BICO Group AB Earnings Call Transcript
()-- -
And thank you so much, everyone, for taking the time today. We really appreciate it. I'm here. I'm Erik Gatenholm, Co-Founder, CEO of BICO, I'm here with Mikael Engblom, Interim CFO. And the purpose of this call is to present the preliminary results and provide a trading update for the group.
I would like to start by, of course, thanking the entire team for the continued strong efforts in Q2, and that's truly been a great pleasure working with everyone serving our global customers around the world. We're on an exciting journey together to create the future of life-saving treatments with our customers and look forward to continuing to serve their laboratory needs. Next slide, please.
With that being said, we now see market slowdowns in emerging biopharma and biotech as a consequence of the recent macroeconomical challenges. While demand for our products remain strong and we can point to healthy underlying demand worldwide in the second quarter, which
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |